Vaso Corporation announced that its subsidiary Vaso Diagnostics, Inc. (d/b/a VasoHealthcare) has extended its sales representation agreement with GE HealthCare through December 31, 2030. The amendment marks the fifth time the parties have renewed the contract and is the first extension to span more than a decade, underscoring the depth of the partnership that began in May 2010.
The agreement covers GE HealthCare’s full portfolio of diagnostic imaging and ultrasound products—including CT, MR, molecular imaging, X‑ray, mammography, and interventional guided solutions—as well as associated service and financial offerings. Vaso’s professional sales segment, which is the company’s primary revenue engine, derives nearly 50 % of total revenue and 100 % of operating profits. In the third quarter of 2025, Vaso reported revenue of $22.7 million, up 9.1 % year‑over‑year, and a net income of $1.7 million, a turnaround from a $1.2 million loss in the same quarter a year earlier. For the full year 2024, revenue reached $86.8 million, a 7 % increase from 2023.
By locking in the GE HealthCare relationship through 2030, Vaso secures a clear revenue runway that reduces concentration risk and supports the company’s ability to deploy cash reserves. The extension reinforces Vaso’s asset‑light, high‑margin business model, which relies on sales expertise rather than capital investment in equipment. Management views the long‑term commitment as a catalyst for continued profitability and a buffer against market volatility.
Dr. Jun Ma, President and CEO, highlighted the company’s strong balance sheet and rising deferred revenue, noting that the extended partnership will sustain momentum in subscription‑based income streams. He emphasized that all three of Vaso’s business segments—professional sales, IT services, and proprietary medical devices—contributed to the year‑over‑year revenue growth in Q3 2025, reflecting a diversified and resilient operating profile.
While the extension itself did not trigger a specific market reaction, it follows a period of positive investor sentiment driven by Vaso’s return to profitability and solid quarterly results. The announcement reinforces confidence in the company’s strategic direction and its ability to maintain high operating margins in a competitive medical‑technology landscape.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.